Relmada Therapeutics Inc. (RLMD)

[VictorMasonIsRight]

Johnston & Johnson NMDA drug approved

Estimate JNJ up 10-15 Billion in last month on anticipated approval (approved yesterday) of their Esketamine inhaler drug
which
1) has a big price tag 4K-6K/ mo,
2) already has generic competition,
3) requires clinic visits and observation.

Both JNJ’s drug and the generic Ketamine are life savers. RLMD will prove to be better but this helps proves the efficacy of the NMDARA mechanism of action
“Esketamine is a non-competitive and subtype non-selective activity-dependent N-methyl-D-aspartate (NMDA) receptor antagonist, which has a novel mechanism of action, meaning it works differently than currently available therapies for depression.”